We searched the MEDLINE, CINAHL, and Cochrane Library databases for English-language randomized controlled trials, systematic reviews, and articles investigating surfactant replacement therapy published between January 1990 and July 2012. By inspection of titles, references having no relevance to the clinical practice guideline were eliminated. The update of this clinical practice guideline is based on 253 clinical trials and systematic reviews, and 12 articles investigating surfactant replacement therapy. The following recommendations are made following the Grading of Recommendations Assessment, Development, and Evaluation scoring system: 1: Administration of surfactant replacement therapy is strongly recommended in a clinical setting where properly trained personnel and equipment for intubation and resuscitation are readily available. 2: Prophylactic surfactant administration is recommended for neonatal respiratory distress syndrome (RDS) in which surfactant deficiency is suspected. 3: Rescue or therapeutic administration of surfactant after the initiation of mechanical ventilation in infants with clinically confirmed RDS is strongly recommended. 4: A multiple surfactant dose strategy is recommended over a single dose strategy. 5: Natural exogenous surfactant preparations are recommended over laboratory derived synthetic suspensions at this time. 6: We suggest that aerosolized delivery of surfactant not be utilized at this time.
forms a layer between the terminal airways/alveolar surfaces and the alveolar gas. In 1961, Klaus and colleagues were the first to isolate alveolar surfactant from bovine lungs, and extracted a phospholipid fraction that displayed a surface active behavior. 4 Ten years later, Gluck et al discovered a technique that allows fetal lung maturity to be measured using the lecithin/sphingomyelin ratio in amniotic fluid. 5 Surfactant is secreted by the type-II pneumocyte and functions to reduce lung collapse during endexhalation by decreasing surface tension within the terminal airways and alveoli. 2, 6 Infants who are born prematurely are more likely to have lungs that are surfactant-deficient at birth. Surfactant deficiency is associated with onset of respiratory distress syndrome (RDS), a major cause of morbidity and mortality in premature infants. 2 Surfactant is also effective in treating infants with meconium aspiration syndrome (MAS), pulmonary hemorrhage, 7 and pneumonia, although the evidence base for their use in these disease processes is much weaker than the primary indication of RDS. 8, 9 Surfactant reduces surface tension, improves lung compliance, and stabilizes lung volumes at a lower transpulmonary pressure. 10 Without surfactant, alveoli may never inflate or may collapse on expiration and require an inordinate amount of force to re-expand on inspiration, leading to the development of severe RDS and air leak syndromes. 2, 6 Surfactant's secondary function is to enhance macrophage activity and mucociliary clearance, and to reduce inflammation. 11 The incidence of RDS is related more to lung immaturity than to gestational age. 12 However, in general, the more premature the infant, the less the surfactant production and the higher the probability for RDS. 12 Mechanical ventilation is often necessary for the treatment of RDS; however, ventilator-induced lung injury can deactivate the production of endogenous surfactant production and compromise the therapeutic effect of surfactant replacement therapy. 13 Direct tracheal instillation of surfactant has been shown to reduce mortality and morbidity in infants with RDS. 14 -29 Exogenous lung surfactant can be either natural or synthetic. Natural surfactant is extracted from animal sources such as bovine or porcine. Synthetic surfactant is manufactured from compounds that mimic natural surfactant properties. Both forms of surfactant replacement are effective at reducing the severity of RDS; however, comparative trials demonstrate greater early improvement in the requirement for ventilatory support and fewer pneumothoraces associated with natural surfactant extract treatment. On clinical grounds, natural surfactant extracts would seem to be the more desirable choice. 30 Two basic strategies for surfactant replacement have emerged: prophylactic or preventive treatment, in which surfactant is administered at the time of birth or shortly thereafter to infants who are at high risk for developing RDS from surfactant deficiency; and rescue or therapeutic treatment, in which surfactant is administered after the initiation of mechanical ventilation in infants with clinically confirmed RDS. 3, 19, 25, 29, 31, 32 Prophylactic surfactant administration to infants at risk of developing RDS is associated with lower risk of air leak and mortality, compared to selective use of surfactant in infants with established RDS. 33 Surfactant administration with brief lung-protective ventilation (followed by extubation to nasal CPAP) for premature infants at risk for developing RDS is associated with a lower incidence of mechanical ventilation, air leak syndromes, and chronic lung disease, compared to selective surfactant and continued mechanical ventilation. 34 Surfactant is traditionally administered by instilling through the ETT, but can also be delivered effectively by injection through the nasopharynx during delivery 35 or by using a thin catheter. 36 Experimental evidence also supports the delivery of some surfactants using a nebulizer. 37 Some early promising studies also look at using surfactant as a delivery agent for the administration of steroids directly to the lungs. 9 
SRT 3.0 SETTINGS

SRT 12.0 FREQUENCY
In infants at high risk of respiratory distress, a policy of multiple doses of surfactant has resulted in greater improvements regarding oxygenation and ventilatory requirements, a decreased risk of necrotizing enterocolitis, and decreased mortality. 77 The ability to give multiple doses of surfactant to infants with ongoing respiratory insufficiency appears to be the most effective treatment regimen. 38 Repeat doses of surfactant are contingent upon the continued diagnosis of neonatal RDS. The frequency with which surfactant replacement is performed should depend upon the clinical status of the patient and the indication for performing the procedure. Additional doses of surfactant, given at 6 -24-hour intervals, may be indicated in infants who experience increasing ventilator requirements or whose conditions fail to improve after the initial dose. 24 (SP-B) . SP-B has been found to reduce surface tension to a greater extent than surfactant protein-C (SP-C). Congenital absence of SP-B at birth is lethal, while SP-C deficiency is not associated with respiratory failure. 78 Older generation synthetic surfactant preparations did not contain any peptidechain proteins such as SP-B, which led to the universal practice of using animal derived surfactants, of which all contained variable amount of SP-B protein. 79 Lucinactant has an SP-B mimicking protein called KL 4 .
13.3
Current data support the use of natural exogenous surfactant over the use of laboratory derived synthetic surfactant. Natural surfactants have shown superior surface absorption and better lowering of alveolar surface tension. In comparative randomized clinical trials, natural surfactant also showed lower oxygen requirement, lower risks of pneumothorax, bronchopulmonary dysplasia (BPD), and death. 79, 80 13.4 Synthetic preparations may have better quality control than natural surfactants, due to the batch-tobatch variations in natural surfactants. The purification procedure for natural surfactants includes extraction with organic solvents to remove hydrophilic proteins SP-A and SP-D. 79 
13.5
There is a small concern with the transmission of prion diseases from natural surfactant preparations. 81 There are some cultural and religious concerns with the use of bovine and/or porcine surfactant preparations.
SRT 14.0 INFECTION CONTROL
14.1 Universal precautions should be implemented. 14.2 Aseptic technique should be practiced and a close catheter system is preferred. 14.3 Appropriate infection control guidelines for the patient should be posted and followed.
SRT 15.0 PROPHYLACTIC VERSUS SELECTIVE TREATMENT OF RDS
15.1 Early surfactant therapy has the advantage of rapidly establishing normal surfactant levels to the lungs and improving lung mechanics, but it can expose an infant who may not develop RDS to intubation, mechanical ventilation, and expose the infant to a drug that may not be necessary. 34 15.2 Selective treatment treats only infants with symptoms of RDS, but this technique has the potential to delay surfactant administration and allow the lung inflammation and protein-containing fluid influx to impair gas exchange. 64 15.3 Prophylactic and early surfactant replacement therapy (within 2 hours of birth) 66 reduces mortality and pulmonary complications in mechanically ventilated infants with RDS, compared to later selective administration. 34 15.4 A lower treatment threshold of F IO 2 Ͻ 0.45 reduces the incidence of air leak syndromes (pulmonary interstitial emphysema and pneumothorax) and BPD. 34 15.5 A higher treatment threshold of F IO 2 Ͼ 0.45 is associated with an increased risk of patent ductus arteriosus. 34 15.5.1 There is evidence of as much as a 22 mm Hg change in mean arterial pressure immediately (within 15 min) of administering surfactant, leading to a hemodynamically important ductus arteriosus. 64 15.6 Early surfactant therapy followed by planned extubation at 1 hour to nasal CPAP significantly reduces the incidence of BPD, compared to selective administration of surfactant. 34, 66 16.0 DEVELOPMENTAL OUTCOMES 16.1 Early treatment of RDS (within 2 hours of birth) to infants Ͻ 30 weeks gestation was associated with fewer long-term clinical pulmonary complications than assignment to a selective administration group. 82 16.2 Surfactant replacement therapy (early or selective methods) has been associated with reduced mortality, without any increase in neuro-developmental disability in survivors at 1-2 year follow-up examinations. 83 (Intubation, Surfactant, Extubation) 17.1.1 This technique features early surfactant replacement therapy with prompt extubation to As soon as the infant's head appears on the perineum or at operative incision, the mother stops pushing and the pharynx and stomach are suctioned with a catheter. The surfactant solution is then instilled into the posterior pharynx through a catheter, without direct laryngoscopy. The infant is then stimulated to breathe as soon as the shoulders and rest of the body are delivered. There have been no randomized controlled trials in humans to validate this technique. Animal studies have confirmed improvement of lung expansion and better survival rates. 84 
DELIVERY TECHNIQUES
INSURE
Laryngeal mask airway (LMA) administration
17.4. 1 The LMA has been identified to require less skill to place than a traditional oral or nasal intubation with an ETT. In an animal study comparing ETT to LMA surfactant delivery, it was reported that surfactant delivery could be accomplished sooner in the LMA group with equivalent efficacy. 85 7 In animal studies, distribution of intratracheally instilled surfactant has been largely determined by gravity, and unaffected by the position of the chest. 89 Therefore, leaving the chest in a horizontal position may result in the most even distribution of surfactant to the lungs.
RECOMMENDATIONS
The recommendations below are made following the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) criteria. 90 18. 
